On Jan. 18, Novartis
- Revenues increased by 19%, driven by growth in all the divisions, particularly pharmaceuticals, which posted strong growth of 15% in the quarter.
- Double-digit growth in top-selling brands like Diovan, Gleevec, and Lotrel led the numbers from the pharmaceutical segment.
- Novartis is a two-star stock in the Motley Fool CAPS stock-rating service. You can add your opinion to the community for free.
(Figures in millions, except per-share data)
Income Statement Highlights*
|
Q4 2006 |
Q4 2005 |
Change |
|
|---|---|---|---|
|
Sales |
$10,058 |
$8,443 |
19.1% |
|
Net Profit |
$1,663 |
$1,352 |
23.0% |
|
EPS |
$0.70 |
$0.57 |
22.8% |
|
Diluted Shares |
2,367.5 |
2,350.1 |
0.7% |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q4 2006 |
Q4 2005 |
Change* |
|
|---|---|---|---|
|
Gross Margin |
71.2% |
72.0% |
(0.8) |
|
Operating Margin |
17.8% |
17.4% |
0.4 |
|
Net Margin |
16.5% |
16.0% |
0.5 |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$7,955 |
$10,933 |
(27.2%) |
|
Accounts Rec. |
$6,161 |
$5,343 |
15.3% |
|
Inventory |
$4,498 |
$3,725 |
20.8% |
|
Liabilities |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Accounts Payable |
$2,487 |
$1,961 |
26.8% |
|
Long-term Debt |
$656 |
$1,319 |
(50.3%) |
Learn the ways of the balance sheet.
Cash Flow Highlights
|
Q4 2006 |
Q4 2005 |
Change |
|
|---|---|---|---|
|
Cash From Ops. |
$2,367 |
$2,220 |
6.6% |
|
Capital Expenditures |
$668 |
$411 |
62.5% |
|
Free Cash Flow |
$1,699 |
$1,809 |
(6.1%) |
Find out why Fools always follow the money.
Related Companies:
-
Johnson & Johnson
(NYSE:JNJ) -
Pfizer
(NYSE:PFE) -
GlaxoSmithKline
(NYSE:GSK)
Related Foolishness:
Johnson & Johnson and GlaxoSmithKline are both winning picks of the Motley Fool Income Investor newsletter service. To see what other great dividend payers have been recommended, take a free 30-day trial today.
Pfizer is an Inside Value pick.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
